{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:47:10Z","timestamp":1768038430601,"version":"3.49.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Recent data suggest that programmed cell death -1 (PD-1) and programmed cell death ligand-1 (PD-L1) are involved in the pathogenesis of Langerhans cell histiocytoma (LCH); however, their contributions are not well established. Also, the involvement of PD-1\/PD-L1 molecules in musculoskeletal LCH remains particularly unclear. The current study aims to characterize the involvement of PD-1\/PD-L1 immune checkpoint system in the pathogenesis of musculoskeletal LCH. PD-1\/PD-L1 expression was evaluated in 6 patients, 3 men and 3 women with a mean age of 13.5\u200ayears, with musculoskeletal LCH who were treated at Kindai University Hospital and Osaka Women's and Children's Hospital between November 2005 and December 2020. The median follow-up period for all patients with musculoskeletal LCH was 41\u200amonths. We surveyed symptoms, number of lesions, treatment modality, and outcomes. Immunostaining for CD4, CD8, PD-1, and PD-L1 was also performed on pathological specimens obtained by biopsy. Multiple lesions were observed in 5 cases, and a single lesion was observed in 1 case. The chief complaint in 5 cases was pain. Four patients underwent spontaneous regression. The other 2 patients received chemotherapy. The outcomes included continuous disease-free (n\u200a=\u200a5) and alive with the disease (n\u200a=\u200a1). The CD4-, CD8-, PD-1-, and PD-L1-positive rates among all specimens were 100%, 100%, 16.6%, and 83.3%, respectively. The CD4\/PD-L1, CD8\/PD-L1, and PD-1\/PD-L1 positive rates in all the specimens were 83.3%, 83.3%, and 16.6%, respectively. We believe that the PD-1\/PD-L1 immune checkpoint molecules may play some role in the microenvironment of musculoskeletal LCH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027650","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T12:21:18Z","timestamp":1635510078000},"page":"e27650","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Characterization of PD-1\/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis"],"prefix":"10.1097","volume":"100","author":[{"given":"Kazuhiko","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kindai University Hospital, Osaka-Sayama City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Osaka Women's and Children's Hospital, Izumi City, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Osaka Women's and Children's Hospital, Izumi City, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","article-title":"Langerhans-cell histiocytosis","volume":"379","author":"Allen","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2017.05.059","article-title":"Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis","volume":"78","author":"Krooks","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J Cell Physiol"},{"key":"R5-20250504","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/atm-20-8141","article-title":"Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.4081\/ejh.2021.3203","article-title":"Characterization of PD-1\/PD-L1 immune checkpoint expression in soft tissue sarcomas","volume":"65","author":"Hashimoto","year":"2021","journal-title":"Eur J Histochem"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.18632\/oncotarget.4378","article-title":"Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1","volume":"6","author":"Gatalica","year":"2015","journal-title":"Oncotarget"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","article-title":"Allen CE; NACHO-LIBRE study group. Clinical responses and persistent BRAFV600E+ blood cells in children with LCH treated with MAPK pathway inhibition","volume":"133","author":"Eckstein","year":"2019","journal-title":"Blood"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e12950","DOI":"10.1111\/sji.12950","article-title":"Immunohistochemical characterization of immune cell infiltration in paediatric and adult Langerhans cell histiocytosis","volume":"00","author":"Paredes","year":"2020","journal-title":"Scand J Immunol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clim.2018.06.004","article-title":"A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis","volume":"194","author":"Mitchell","year":"2018","journal-title":"Clin Immunol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1002\/cam4.2596","article-title":"CD4\/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/15384047.2018.1450116","article-title":"Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer","volume":"19","author":"Li","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1111\/cas.13817","article-title":"Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment","volume":"109","author":"Kobayashi","year":"2018","journal-title":"Cancer Sci"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/107327481402100409","article-title":"Langerhans cell histiocytosis","volume":"21","author":"Grana","year":"2014","journal-title":"Cancer Control"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:10:57Z","timestamp":1746331857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027650"}},"subtitle":["A retrospective study"],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":22,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027650","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"2021-06-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}